ArticleDigestive diseases and sciences2019
Earlier Anti-Tumor Necrosis Factor Therapy of Crohn's Disease Correlates with Slower Progression of Bowel Damage.
Article in Digestive diseases and sciences, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Systematic review and meta-analysis: efficacy and safety of early biologic treatment in adult and paediatric patients with Crohn's disease.Alimentary pharmacology & therapeutics · 2020Pooled it
- Redefining Early Intervention and the Window of Opportunity in Crohn's Disease.Gastroenterology & hepatology · 2026Article
- Early Biologic Initiation After Chronic Pouch Inflammation Diagnosis Does Not Impact Clinical Outcomes.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2023Article
- Can we change the natural course of inflammatory bowel disease?Therapeutic advances in gastroenterology · 2023Review
- Earlier anti-TNF therapy reduces the risk of malnutrition associated with alterations in body composition in patients with Crohn's disease.Frontiers in nutrition · 2023Article
- A scoping review on early inflammatory bowel disease: definitions, pathogenesis, and impact on clinical outcomes.Therapeutic advances in gastroenterology · 2022Article
- The Effect of Early vs Delayed Initiation of Adalimumab on Remission Rates in Patients With Crohn's Disease With Poor Prognostic Factors: The MODIFY Study.Crohn's & colitis 360 · 2021Article
- Tumour necrosis factor inhibitors in inflammatory bowel disease: the story continues.Therapeutic advances in gastroenterology · 2021Review
- Various Forms of Tuberculosis in Patients with Inflammatory Bowel Diseases Treated with Biological Agents.International journal of inflammation · 2021Review
- Efficacy of early intervention on the bowel damage and intestinal surgery of Crohn's disease, based on the Lémann index.BMC gastroenterology · 2020Article
- Timely Use of Biologics in Early Crohn's Disease: The Return of "Hit Hard and Early"?Digestive diseases and sciences · 2019Article
- Diagnosis and natural history of preclinical and early inflammatory bowel disease.Annals of gastroenterologyReview
Corrections and comments
- Commented on by
Authors and funding
10 authors.
Funding
Abstract
introductionCrohn's disease (CD) follows a relapsing and remitting course incurring cumulative bowel damage over time. The question of whether or not the timing of the initiating biologic therapy affects long-term disease progression remains unanswered. Herein, we calculated rates of change in the Lémann index-which quantifies accumulated bowel damage-as a function of the time between the disease onset and initiation of biologic therapy. We aimed to explore the impact of the earlier introduction of biologics on the rate of progression of long-term cumulative bowel damage.
methodsMedical records of CD patients treated during 2009-2014 at The Mount Sinai Hospital were queried. Inclusion criteria were two comprehensive assessments allowing calculation of the index at t
resultsA total of 88 patients were studied: 58 Bio-pre-t
conclusionsEarlier introduction of biologics tended to correlate with the slower progression of bowel damage in CD, reflected by the reduced rate of Lémann index progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.